Emerging evidence underscores that dual checkpoint inhibition significantly heightens the incidence of endocrinopathies relative to monotherapy, with adrenal insufficiency more frequently reported in patients receiving anti-PD-1/LAG-3 combinations than in those treated with anti-PD-1 monotherapy [30]. Here, PDCD1 is linked to endocrine system disorder.